ω-3多不饱和脂肪酸对肝癌病人术后影响的研究现状

Current researches ofω-3 polyunsaturated fatty acids and postoperative primary liver cancer patients

全球肝癌的发病率及死亡率较高,尽管早期发现并行根治性治疗的病人5年生存率可达60%以上,但术后应激、并发症以及肿瘤复发等严重影响术后病人的生活质量和生存周期。ω-3多不饱和脂肪酸(ω-3 polyunsaturated fatty acids,ω-3 PUFAs)由于具有调节脂质代谢、降低氧化应激、维持肠道健康等方面的作用,不仅被广泛作为商业食品补充剂用于预防肝癌的发生发展,还作为肠外营养脂肪乳剂的有效成分应用于术后病人。现有的研究表明,ω-3 PUFAs应用于肝癌术后病人可降低炎症反应、保护肝功能、减少感染等并发症的发生,从而缩短病人的住院时间。对于具有高危复发因素的病人,术后长期服用ω-3 PUFAs或联合其他辅助治疗也可能产生相应的有益效果,例如提高辅助治疗效果以及降低药物的不良反应等。但也有研究证实了与前研究结果相驳论之处。因此,ω-3 PUFAs的作用机制是复杂的,许多调控环节仍有待进一步研究,且其对肝癌病人术后临床相关指标的影响也需要大量的数据去证实。

The global incidence and mortality of primary liver cancer(PLC)are relatively high.Although 5-year survival rate of patients with early detection and curative treatment surpasses 60%,postoperative stress,complications and tumor recurrence seriously affect the quality-of-life and survival of patients post-operation.Due to their functions of regulating lipid metabolism,lowering oxidative stress and maintaining intestinal health,ω-3 PUFAs were not only extensively applied as a commercial food supplement for preventing the development of liver cancer but also as an active component of parenteral nutrition fat emulsion in postoperative patients.Existing studies have shown that postoperative application of omega-3 PUFAs in PLC patients could blunt inflammatory response,protect liver function,reduce the occurrence of infection and thus shorten the length of hospital stay.In patients at a high risk for recurrence,long-term use of omega-3 PUFAs or in combination with adjuvant therapy offered beneficial effects of mproved adjuvant therapy and prevention of adverse toxic effects.However,another study contradicted the previous findings.Thus the mechanism of action of omega-3 PUFAs is so complex that many regulatory links remain to be further elucidated.Its impact on clinical parameters of postoperative PLC patients should be confirmed with a large amount of data.